38 related articles for article (PubMed ID: 11423937)
1. CD30 plays a role in T-dependent immune response and T cell proliferation.
Cui D; Zhang Y; Chen L; Du H; Zheng B; Huang M; Li X; Wei J; Chen Q
FASEB J; 2024 Jan; 38(1):e23365. PubMed ID: 38069862
[TBL] [Abstract][Full Text] [Related]
2. CAR-T cell potency: from structural elements to vector backbone components.
Mazinani M; Rahbarizadeh F
Biomark Res; 2022 Sep; 10(1):70. PubMed ID: 36123710
[TBL] [Abstract][Full Text] [Related]
3. Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors.
Abken H
Hum Gene Ther; 2021 Oct; 32(19-20):1011-1028. PubMed ID: 34405686
[TBL] [Abstract][Full Text] [Related]
4. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.
Braendstrup P; Levine BL; Ruella M
Cytotherapy; 2020 Feb; 22(2):57-69. PubMed ID: 32014447
[TBL] [Abstract][Full Text] [Related]
5. Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas.
Poggio T; Duyster J; Illert AL
Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30231561
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating HLA-matched CD4(+) T cells retargeted against Hodgkin and Reed-Sternberg cells.
Rengstl B; Schmid F; Weiser C; Döring C; Heinrich T; Warner K; Becker PS; Wistinghausen R; Kameh-Var S; Werling E; Billmeier A; Seidl C; Hartmann S; Abken H; Küppers R; Hansmann ML; Newrzela S
Oncoimmunology; 2016 Jun; 5(6):e1160186. PubMed ID: 27471632
[TBL] [Abstract][Full Text] [Related]
7. Strategies to genetically engineer T cells for cancer immunotherapy.
Spear TT; Nagato K; Nishimura MI
Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
[TBL] [Abstract][Full Text] [Related]
8. Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack.
Hombach AA; Görgens A; Chmielewski M; Murke F; Kimpel J; Giebel B; Abken H
Mol Ther; 2016 Aug; 24(8):1423-34. PubMed ID: 27112062
[TBL] [Abstract][Full Text] [Related]
9. Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor.
Komarova S; Roth J; Alvarez R; Curiel DT; Pereboeva L
J Ovarian Res; 2010 May; 3():12. PubMed ID: 20500878
[TBL] [Abstract][Full Text] [Related]
10. The promise and potential pitfalls of chimeric antigen receptors.
Sadelain M; Brentjens R; Rivière I
Curr Opin Immunol; 2009 Apr; 21(2):215-23. PubMed ID: 19327974
[TBL] [Abstract][Full Text] [Related]
11. Costimulation tunes tumor-specific activation of redirected T cells in adoptive immunotherapy.
Hombach A; Abken H
Cancer Immunol Immunother; 2007 May; 56(5):731-7. PubMed ID: 17143613
[TBL] [Abstract][Full Text] [Related]
12. Engineering T cells for cancer therapy.
Mansoor W; Gilham DE; Thistlethwaite FC; Hawkins RE
Br J Cancer; 2005 Nov; 93(10):1085-91. PubMed ID: 16251873
[TBL] [Abstract][Full Text] [Related]
13. A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3zeta-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells.
Hombach A; Schlimper C; Sievers E; Frank S; Schild HH; Sauerbruch T; Schmidt-Wolf IG; Abken H
Gut; 2006 Aug; 55(8):1156-64. PubMed ID: 16188919
[TBL] [Abstract][Full Text] [Related]
14. T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30(+) cutaneous lymphoma cells.
Hombach A; Muche JM; Gerken M; Gellrich S; Heuser C; Pohl C; Sterry W; Abken H
Gene Ther; 2001 Jun; 8(11):891-5. PubMed ID: 11423937
[TBL] [Abstract][Full Text] [Related]
15. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
[TBL] [Abstract][Full Text] [Related]
16. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
17. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30.
Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
Cancer Res; 1998 Mar; 58(6):1116-9. PubMed ID: 9515791
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
19. Immunoregulatory events in the skin of patients with cutaneous T-cell lymphoma.
Hansen ER
Arch Dermatol; 1996 May; 132(5):554-61. PubMed ID: 8624153
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
